Published in Neuroendocrinology on February 20, 2007
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology (2008) 3.04
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer (2008) 2.11
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology (2012) 1.86
Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg (2011) 1.71
Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg (2012) 1.55
Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol (2011) 1.35
Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management. World J Gastrointest Endosc (2010) 1.33
The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg (2011) 1.21
Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol (2009) 1.12
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology (2016) 1.09
Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) (2013) 1.00
Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol (2012) 0.93
Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg (2011) 0.93
Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol (2012) 0.92
Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med (2016) 0.92
The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg (2011) 0.89
Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors. World J Surg (2012) 0.88
Diagnosis of Zollinger-Ellison syndrome: increasingly difficult. World J Gastroenterol (2012) 0.85
Treatment of gastroenteropancreatic neuroendocrine tumors. Virchows Arch (2007) 0.83
Surgical treatment of gastrinomas: a single-centre experience. HPB (Oxford) (2012) 0.83
Zollinger-Ellison syndrome: classical considerations and current controversies. Oncologist (2013) 0.82
Primary hepatic gastrinoma: an unusual case of zollinger-ellison syndrome. Gastroenterol Hepatol (N Y) (2010) 0.82
Important of case-reports/series, in rare diseases: Using neuroendocrine tumors as an example. World J Clin Cases (2014) 0.81
Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacother (2013) 0.81
Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. Int J Endocr Oncol (2016) 0.79
Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest (2014) 0.78
Medical treatment of gastroenteropancreatic neuroendocrine tumors. Cancers (Basel) (2012) 0.78
Endocrine neoplasms in familial syndromes of hyperparathyroidism. Endocr Relat Cancer (2016) 0.78
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. Am J Nucl Med Mol Imaging (2014) 0.77
Syndromic versus non-syndromic sporadic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior. Virchows Arch (2015) 0.76
Medical treatment of gastrinomas. Wien Klin Wochenschr (2007) 0.76
Mechanism of acid hypersecretion post curative gastrinoma resection. Dig Dis Sci (2010) 0.76
Practical management and treatment of pancreatic neuroendocrine tumors. Gland Surg (2014) 0.76
Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol (2016) 0.75
Selective Arterial Embolization of Liver Metastases from Gastrinomas: A Single-Centre Experience. ISRN Hepatol (2013) 0.75
Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am (2015) 0.75
Primary jejunal gastrinoma: a case report and review of the literature. World J Surg Oncol (2015) 0.75
A Perplexing Case of Abdominal Pain That Led to the Diagnosis of Zollinger-Ellison Syndrome. Case Rep Gastrointest Med (2017) 0.75
Comprehensive treatment of a functional pancreatic neuroendocrine tumor with multifocal liver metastases. Chin J Cancer Res (2014) 0.75
Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature. BMC Gastroenterol (2014) 0.75
Zollinger-Ellison Syndrome: A Rare Case of Chronic Diarrhea. Gastroenterology Res (2016) 0.75
Diagnosis and Treatment of Gastrinomas in Multiple Endocrine Neoplasia Type 1 (MEN-1). Cancers (Basel) (2012) 0.75
Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy. Pancreas (2017) 0.75
Endoscopic treatment of duodenal neuroendocrine tumors. Clin Endosc (2013) 0.75
Surgical treatment of multiple spine metastases from gastrinoma. Evid Based Spine Care J (2011) 0.75
Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience (2017) 0.75
Synchronous Peripancreatic Lymph Node Gastrinoma and Gastric Neuroendocrine Tumor Type 2. Clin Endosc (2016) 0.75
Misdiagnosed gastrinoma: A case report. Oncol Lett (2014) 0.75
Zollinger-Ellison Syndrome in a 12-year-old Child. J Indian Assoc Pediatr Surg (2017) 0.75
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
International network of cancer genome projects. Nature (2010) 20.35
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 5.40
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol (2003) 4.31
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci (2004) 4.13
Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol (2006) 3.46
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut (2005) 3.32
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg (2006) 3.05
Increased number of islet-associated macrophages in type 2 diabetes. Diabetes (2007) 3.01
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol (2009) 2.94
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging (2009) 2.48
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2004) 2.45
Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care (2008) 2.36
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res (2007) 2.16
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut (2011) 2.14
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology (2012) 2.12
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]. Gastroenterol Clin Biol (2002) 2.04
Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence, and characterization of beta-cell changes. Am J Surg Pathol (2005) 2.04
Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts. Eur J Nucl Med Mol Imaging (2011) 2.01
ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology (2012) 1.99
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res (2007) 1.98
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol (2008) 1.97
18F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids Versus Pulmonary Hamartomas. Clin Nucl Med (2016) 1.94
Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. J Clin Endocrinol Metab (2004) 1.92
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology (2009) 1.92
Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut (2006) 1.91
Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol (2007) 1.87
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology (2012) 1.86
Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer (2010) 1.85
Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma. Haematologica (2006) 1.84
Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum (2011) 1.82
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res (2010) 1.81
Superiority of small islets in human islet transplantation. Diabetes (2007) 1.76
Pulmonary resection for metastases of colorectal adenocarcinoma. Ann Thorac Surg (2010) 1.76
Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol (2006) 1.71
Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch (2007) 1.70
Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene (2002) 1.67
Advantages of recurrent laryngeal nerve identification in thyroidectomy and parathyroidectomy and the importance of preoperative and postoperative laryngoscopic examination in more than 1000 nerves at risk. Laryngoscope (2002) 1.66
Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology (2007) 1.65
Hypoparathyroidism after total thyroidectomy: a prospective study. Arch Surg (2008) 1.63
HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood (2005) 1.62
Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62
Intrapulmonary arteriovenous shunting may be a universal phenomenon in patients with the superior cavopulmonary anastomosis: a radionuclide study. Heart (2000) 1.59
DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One (2013) 1.57
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med (2005) 1.55
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy? Clin Endocrinol (Oxf) (2002) 1.53
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med (2005) 1.51
Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres. Eur J Nucl Med Mol Imaging (2010) 1.51
Lower moiety heminephroureterectomy in the duplex refluxing kidney: the accuracy of isotopic scintigraphy in functional assessment. Br J Urol (1998) 1.50
Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab (2007) 1.49
Chemotherapy in elderly patients with colorectal cancer. Oncologist (2008) 1.48
Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med (2009) 1.46
Assessment of inactive, active and mixed atherosclerotic plaques by 18F-FDG-PET; an age group-based correlation with cardiovascular risk factors. Int J Cardiovasc Imaging (2008) 1.45
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med (2006) 1.44
Lymphotoxin β receptor signaling promotes development of autoimmune pancreatitis. Gastroenterology (2012) 1.43
Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol (2011) 1.42
Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest (2008) 1.42
The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch (2010) 1.42
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology (2009) 1.42
⁶⁸Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors. Endocrine (2013) 1.41
Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2007) 1.40
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology (2012) 1.38
MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer (2010) 1.38
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta (2007) 1.38
The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.36
Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica (2008) 1.35
Evaluation of novel whole-body high-resolution rodent SPECT (Linoview) based on direct acquisition of linogram projections. J Nucl Med (2005) 1.34
Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol (2014) 1.33
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med (2002) 1.33
Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol (2006) 1.33
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer (2010) 1.30
Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging (2009) 1.30
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology (2009) 1.28
Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells. Biosci Rep (2011) 1.28
Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology (2005) 1.28
ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nat Commun (2013) 1.27
Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol (2012) 1.26